Scopolamine should not be given as a premedication in patients with which neurologic disease?

Scopolamine should not be given as a premedication in patients with which neurologic disease?

• A. Parkinson's disease
• B. Alzheimer's disease
• C. Multiple sclerosis
• D. Narcolepsy

Answer: (B)

Central anticholinergic effects on cognition are the key issue. Scopolamine blocks muscarinic receptors in the brain and crosses the blood–brain barrier, reducing acetylcholine activity which is crucial for memory, attention, and learning. In Alzheimer's disease, there is already a loss of cholinergic neurons and diminished acetylcholine signaling. Adding a strong CNS anticholinergic like scopolamine further impairs cognition and increases delirium risk, making it unsuitable as a premedication in these patients. Other neurologic conditions don’t carry that same level of inherent vulnerability to acetylcholine disruption, so the concern is greatest with Alzheimer's disease.

Central anticholinergic effects on cognition are the key issue. Scopolamine blocks muscarinic receptors in the brain and crosses the blood–brain barrier, reducing acetylcholine activity which is crucial for memory, attention, and learning. In Alzheimer's disease, there is already a loss of cholinergic neurons and diminished acetylcholine signaling. Adding a strong CNS anticholinergic like scopolamine further impairs cognition and increases delirium risk, making it unsuitable as a premedication in these patients. Other neurologic conditions don’t carry that same level of inherent vulnerability to acetylcholine disruption, so the concern is greatest with Alzheimer's disease.